Industry News
Biotechnology Industry News
Fresh from a European cancer…
Fresh from a European cancer conference that was all about antibody-drug conjugates, GSK has turned to French biotech Syndivia for a preclinical prostate cancer prospect.
Almost a year after buying Kate…
Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far.
Long regarded as one of Japan’s…
Long regarded as one of Japan’s best-kept biotech secrets, JCR Pharmaceuticals, now in its 50th year, is stepping onto the global stage. With a proven platform for delivering therapeutics across the blood-brain barrier (BBB), a
Just as Adverum’s cash reserves…
Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.
The company will use the fresh…
The company will use the fresh funding to build out its pipeline and advance its clinical candidates for Glanzmann thrombasthenia and von Willebrand disease.
Biogen plans to beef up its…
Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.
Sanofi has dropped its respiratory…
Sanofi has dropped its respiratory syncytial virus vaccine for toddlers after the candidate underperformed in a phase 3 study.
Ophthalmology biotech veteran…
Ophthalmology biotech veteran Gregory Kunst has found his next venture after being removed as CEO of Aurion Biotech during its contentious sale to Alcon. Kunst is now CEO of Valitor, replacing interim CEO Michael Ostrach.
Inhibrx Biosciences’ antibody…
Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved treatments, prompting the San Diego biotech to plot a submission to the FDA in
Clinical development is undergoing…
Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue to rise.
Regeneron has given up on a CAR-T…
Regeneron has given up on a CAR-T candidate acquired from 2seventy last year, before it finished its phase 1/2 lymphoma study.
Ventyx Biosciences’…
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week.
Roche has dropped five Chugai…
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions that the Japanese business took earlier this year.
Recorded at Fierce Biotech Week,…
Recorded at Fierce Biotech Week, this episode of "The Top Line" cuts past the pitch—leaders from past Fierce 15 companies talk about what’s working in biotech right now and what isn’t.
Moderna is halting development of…
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a post-market release.
iRegene cracks the code on…
iRegene cracks the code on scalable cell therapy. Its chemical induction platform enables "off-the-shelf" treatments, validated by strong Phase I PD data.
FDA approves IND based on human…
FDA approves IND based on human vascularized organoid efficacy data, marking a milestone in replacing animal POC testing.
In a mixed interim data drop,…
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis.
Alector Therapeutics is shelving a…
Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). To pivot away from latozinemab, the Bay Area biotech is laying
Sanofi’s $1.7 billion rare…
Sanofi’s $1.7 billion rare disease bet has delivered a phase 2 win. Efdoralprin alfa beat the standard of care on primary and key secondary endpoints, positioning the drugmaker to talk to regulators about the next